- Home
- CLLS vs BRW Comparison
CLLS vs BRW Comparison
Compare CLLS & BRW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- BRW
- Stock Information
- Founded
- CLLS 1999
- BRW 1987
- Country
- CLLS France
- BRW United States
- Employees
- CLLS N/A
- BRW N/A
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- BRW Trusts Except Educational Religious and Charitable
- Sector
- CLLS Health Care
- BRW Finance
- Exchange
- CLLS Nasdaq
- BRW Nasdaq
- Market Cap
- CLLS 299.0M
- BRW 355.1M
- IPO Year
- CLLS 2007
- BRW N/A
- Fundamental
- Price
- CLLS $3.22
- BRW $7.24
- Analyst Decision
- CLLS Buy
- BRW
- Analyst Count
- CLLS 1
- BRW 0
- Target Price
- CLLS $8.00
- BRW N/A
- AVG Volume (30 Days)
- CLLS 134.5K
- BRW 222.1K
- Earning Date
- CLLS 11-07-2025
- BRW 01-01-0001
- Dividend Yield
- CLLS N/A
- BRW 15.59%
- EPS Growth
- CLLS N/A
- BRW N/A
- EPS
- CLLS N/A
- BRW N/A
- Revenue
- CLLS $63,438,000.00
- BRW N/A
- Revenue This Year
- CLLS N/A
- BRW N/A
- Revenue Next Year
- CLLS $58.00
- BRW N/A
- P/E Ratio
- CLLS N/A
- BRW N/A
- Revenue Growth
- CLLS 223.09
- BRW N/A
- 52 Week Low
- CLLS $1.10
- BRW $7.15
- 52 Week High
- CLLS $5.48
- BRW $8.30
- Technical
- Relative Strength Index (RSI)
- CLLS 41.41
- BRW 33.77
- Support Level
- CLLS $3.12
- BRW $7.25
- Resistance Level
- CLLS $3.79
- BRW $7.46
- Average True Range (ATR)
- CLLS 0.19
- BRW 0.09
- MACD
- CLLS -0.08
- BRW 0.02
- Stochastic Oscillator
- CLLS 13.43
- BRW 24.14
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About BRW Saba Capital Income & Opportunities Fund SBI
Saba Capital Income & Opportunities Fund is a diversified, closed-end management investment company. It seeks to provide investors with a high level of current income, with a secondary goal of capital appreciation. It invests globally in debt and equity securities of public and private companies, which includes, investing in closed-end funds, public and private debt instruments, and other securities.